骨髄線維症（MF）の世界市場レポート 2025年

骨髄線維症（MF）の市場規模は、今後数年間で安定した成長が見込まれます。2029年の年間平均成長率（CAGR）は3.2％で、17億6,000万米ドルに成長します。予測期間中の成長は、個別化治療アプローチに対する需要の高まり、遺伝子・細胞治療の臨床試験の増加、併用療法の拡大、希少疾患に対するヘルスケア適用の拡大、血液医療への投資の増加などの要因によるものと考えられます。この期間に予想される主な動向としては、遺伝子編集技術の発展、線維症治療薬の革新、次世代JAK阻害剤の開発、骨髄線維症に対する免疫療法への関心の高まり、創薬における人工知能の利用拡大などが挙げられます。

標的治療薬に対する需要の高まりが、骨髄線維症（MF）市場の成長を牽引すると予想されます。標的療法は、個人の遺伝的、環境的、ライフスタイル的要因に基づいて治療やヘルスケアの決定を調整するアプローチです。これらの治療に対する需要の高まりは、より正確で効果的な個別化治療を可能にするゲノム、バイオテクノロジー、データ解析の進歩によって後押しされています。骨髄線維症は、JAK-STATシグナル伝達などの重要な分子経路を浮き彫りにすることで、標的治療の開発における重要な例となっています。これらの経路は、JAK阻害剤（ルキソリチニブ、フェドラチニブ、パクリチニブ）のような精密治療の設計を可能にし、症状の管理や病気の進行を遅らせるのに役立っています。例えば、2024年4月、米国遺伝子・細胞治療学会は、臨床開発中の治療法の数が増加し、中でも第I相治療法が11%増と最も顕著な伸びを示し、2022年第4四半期以来の高い伸び率を示したと報告しました。その結果、標的治療薬に対する需要の高まりが骨髄線維症市場の成長を牽引し続けると予想されます。

骨髄線維症市場の企業は、治療効果を高め、疾患の進行に対処し、患者の転帰を改善するために、標的療法の拡大に注力しています。例えば、JAK1/JAK2阻害剤はヤヌスキナーゼ経路を標的として骨髄線維症の炎症と異常血球産生を抑制し、ACVR1阻害剤はアクチビン受容体様キナーゼ2（ALK2）を阻害して骨髄線維化と疾患進行を制御します。特筆すべき例は、2023年9月に英国の製薬会社GSK plcが米国食品医薬品局（FDA）からOjjaara（モメロチニブ）の承認を取得したことです。この治療は、中リスクまたは高リスクの骨髄線維症患者を対象としており、JAK1/JAK2とACVR1の両方を標的とする二重の作用機序を持っています。炎症経路を制御し、ヘモグロビン濃度を改善し、輸血の必要性を減らします。今回の承認は、治療の選択肢を拡大し、特に貧血に悩む患者にとって、この疾患における重要なアンメット・ニーズであるMFの管理に新たな基準を設定するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界骨髄線維症（MF） PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の骨髄線維症（MF）市場：成長率分析
• 世界の骨髄線維症（MF）市場の実績：規模と成長, 2019-2024
• 世界の骨髄線維症（MF）市場の予測：規模と成長, 2024-2029, 2034F
• 世界骨髄線維症（MF）総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の骨髄線維症（MF）市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• Jak阻害剤
• 免疫調節薬
• ヒドロキシウレア
• その他の薬物の種類
• 世界の骨髄線維症（MF）市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• その他の治療の種類
• 世界の骨髄線維症（MF）市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の骨髄線維症（MF）市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界の骨髄線維症（MF）市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の骨髄線維症（MF）市場Jak阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ルキソリチニブ
• フェドラチニブ
• モメロチニブ
• イタシチニブ
• 世界の骨髄線維症（MF）市場免疫調節剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• サリドマイド
• レナリドミド
• ポマリドミド
• 世界の骨髄線維症（MF）市場、ヒドロキシウレアの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口ヒドロキシウレア
• 注射用ヒドロキシウレア
• 世界の骨髄線維症（MF）市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 赤血球造血刺激因子製剤（ESA）
• ダナゾール
• モノクローナル抗体
• 化学療法剤

第7章 地域別・国別分析

• 世界の骨髄線維症（MF）市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の骨髄線維症（MF）市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 骨髄線維症（MF）市場：競合情勢
• 骨髄線維症（MF）市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol-Myers Squibb Company
• Novartis AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Gilead Sciences Inc.
• A. Menarini Industrie Farmaceutiche Riunite S.r.l.
• Incyte Corporation
• Sobi Inc.
• MorphoSys AG
• CTI BioPharma Corp.
• Suzhou Zelgen Biopharmaceutical Co. Ltd.
• NS Pharma Inc.
• Impact Biomedicines Inc.
• Kartos Therapeutics Inc.
• Geron Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 骨髄線維症（MF）市場2029：新たな機会を提供する国
• 骨髄線維症（MF）市場2029：新たな機会を提供するセグメント
• 骨髄線維症（MF）市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Myelofibrosis (MF) is a rare bone marrow disorder marked by the excessive formation of scar tissue, which impairs the normal production of blood cells. This condition can cause anemia, an enlarged spleen, and symptoms such as fatigue, night sweats, and bone pain.

The primary drug types used for treating myelofibrosis include JAK inhibitors, immunomodulators, hydroxyurea, and other therapies. JAK inhibitors are medications that block Janus kinase enzymes, which are involved in signaling pathways responsible for inflammation, immune response, and cell growth. These inhibitors are commonly used to treat conditions such as rheumatoid arthritis and myelofibrosis. Treatment options for MF include chemotherapy, targeted therapy, and other types of treatment. The medications can be administered orally, parenterally, or through other routes. They are distributed via hospital pharmacies, online pharmacies, and retail pharmacies, with key end users including hospitals, home care settings, specialty clinics, and other healthcare facilities.

The myelofibrosis (MF) market research report is one of a series of new reports from The Business Research Company that provides myelofibrosis (MF) market statistics, including the myelofibrosis (MF) industry global market size, regional shares, competitors with the myelofibrosis (MF) market share, detailed myelofibrosis (MF) market segments, market trends, and opportunities, and any further data you may need to thrive in the myelofibrosis (MF) industry. This myelofibrosis (MF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The myelofibrosis (MF) market size has grown steadily in recent years. It will grow from $1.50 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 3.5%. The growth during the historic period can be attributed to factors such as the rising prevalence of myeloproliferative neoplasms, greater awareness and earlier diagnosis, the growing adoption of JAK inhibitors, improved access to bone marrow transplants, and more regulatory approvals for new therapies.

The myelofibrosis (MF) market size is expected to see steady growth in the next few years. It will grow to $1.76 billion in 2029 at a compound annual growth rate (CAGR) of 3.2%. The growth during the forecast period can be attributed to factors such as the rising demand for personalized treatment approaches, an increase in clinical trials for gene and cell therapies, a growing use of combination therapies, expanding healthcare coverage for rare diseases, and increased investment in hematology care. Key trends expected in this period include advancements in gene-editing technologies, innovations in fibrosis-targeting drugs, the development of next-generation JAK inhibitors, growing interest in immunotherapy for myelofibrosis, and the expanding use of artificial intelligence in drug discovery.

The growing demand for targeted therapies is expected to drive the growth of the myelofibrosis (MF) market. Targeted therapies are an approach that tailors treatments and healthcare decisions based on an individual's genetic, environmental, and lifestyle factors. The increasing demand for these therapies is fueled by advancements in genomics, biotechnology, and data analytics, which allow for more precise, effective, and personalized treatments. Myelofibrosis serves as a key example in the development of targeted therapies by highlighting critical molecular pathways, such as JAK-STAT signaling. These pathways enable the design of precision treatments such as JAK inhibitors (Ruxolitinib, Fedratinib, and Pacritinib) that help manage symptoms and slow the progression of the disease. For instance, in April 2024, the American Society of Gene & Cell Therapy reported that the number of therapies in clinical development has grown, with Phase I therapies showing the most significant increase, rising by 11%-the highest growth rate since Q4 2022. As a result, the growing demand for targeted therapies is expected to continue driving growth in the myelofibrosis market.

Companies in the myelofibrosis market are focusing on expanding targeted therapies to enhance treatment efficacy, address disease progression, and improve patient outcomes. JAK1/JAK2 inhibitors, for example, target the Janus kinase pathway to reduce inflammation and abnormal blood cell production in myelofibrosis, while ACVR1 inhibitors block activin receptor-like kinase 2 (ALK2) to regulate bone marrow fibrosis and disease progression. A notable example is in September 2023 when GSK plc, a UK-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Ojjaara (momelotinib). This treatment, designed for patients with intermediate- or high-risk myelofibrosis, has a dual mechanism of action that targets both JAK1/JAK2 and ACVR1. It helps regulate inflammatory pathways and improves hemoglobin levels, reducing the need for transfusions. This approval expands treatment options and sets a new standard in the management of MF, particularly for patients struggling with anemia, a significant unmet need in the disease landscape.

In February 2024, Novartis AG, a Swiss pharmaceutical company, acquired MorphoSys AG for EUR 2.7 billion ($2.91 billion). The acquisition enables Novartis to gain full ownership of pelabresib (CPI-0610), a promising treatment for myelofibrosis when combined with ruxolitinib, and tulmimetostat (CPI-0209), an investigational dual EZH1/EZH2 inhibitor being evaluated for solid tumors and lymphomas. This acquisition strengthens Novartis' oncology pipeline by adding innovative therapies aimed at addressing critical unmet medical needs in the field of oncology and myelofibrosis.

Major players in the myelofibrosis (MF) market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., A. Menarini Industrie Farmaceutiche Riunite S.r.l., Incyte Corporation, Sobi Inc., MorphoSys AG, CTI BioPharma Corp., Suzhou Zelgen Biopharmaceutical Co. Ltd., NS Pharma Inc., Impact Biomedicines Inc., Kartos Therapeutics Inc., Geron Corporation.

North America was the largest region in the myelofibrosis (MF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in myelofibrosis (MF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the myelofibrosis (MF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myelofibrosis (MF) market consists of revenues earned by entities by providing services such as diagnostic services, patient support programs, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The myelofibrosis (MF) market also includes sales of hematological diagnostic tools, novel fibrosis-targeting drugs, and evolving regenerative therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myelofibrosis (MF) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myelofibrosis (mf) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myelofibrosis (mf) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myelofibrosis (mf) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Jak Inhibitor; Immunomodulators; Hydroxyurea; Other Drug Types
• 2) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Jak Inhibitor: Ruxolitinib; Fedratinib; Momelotinib; Itacitinib
• 2) By Immunomodulators: Thalidomide; Lenalidomide; Pomalidomide
• 3) By Hydroxyurea: Oral Hydroxyurea; Injectable Hydroxyurea
• 4) By Other Drug Types: Erythropoiesis-Stimulating Agents (ESAs); Danazol; Monoclonal Antibodies; Chemotherapy Agents
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myelofibrosis (MF) Market Characteristics

3. Myelofibrosis (MF) Market Trends And Strategies

4. Myelofibrosis (MF) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Myelofibrosis (MF) Growth Analysis And Strategic Analysis Framework

• 5.1. Global Myelofibrosis (MF) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Myelofibrosis (MF) Market Growth Rate Analysis
• 5.4. Global Myelofibrosis (MF) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Myelofibrosis (MF) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Myelofibrosis (MF) Total Addressable Market (TAM)

6. Myelofibrosis (MF) Market Segmentation

• 6.1. Global Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Jak Inhibitor
• Immunomodulators
• Hydroxyurea
• Other Drug Types
• 6.2. Global Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Targeted Therapy
• Other Treatment Types
• 6.3. Global Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Routes Of Administration
• 6.4. Global Myelofibrosis (MF) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• 6.5. Global Myelofibrosis (MF) Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.6. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Jak Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ruxolitinib
• Fedratinib
• Momelotinib
• Itacitinib
• 6.7. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Thalidomide
• Lenalidomide
• Pomalidomide
• 6.8. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Hydroxyurea, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Hydroxyurea
• Injectable Hydroxyurea
• 6.9. Global Myelofibrosis (MF) Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erythropoiesis-Stimulating Agents (ESAs)
• Danazol
• Monoclonal Antibodies
• Chemotherapy Agents

7. Myelofibrosis (MF) Market Regional And Country Analysis

• 7.1. Global Myelofibrosis (MF) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Myelofibrosis (MF) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Myelofibrosis (MF) Market

• 8.1. Asia-Pacific Myelofibrosis (MF) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Myelofibrosis (MF) Market

• 9.1. China Myelofibrosis (MF) Market Overview
• 9.2. China Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Myelofibrosis (MF) Market

• 10.1. India Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Myelofibrosis (MF) Market

• 11.1. Japan Myelofibrosis (MF) Market Overview
• 11.2. Japan Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Myelofibrosis (MF) Market

• 12.1. Australia Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Myelofibrosis (MF) Market

• 13.1. Indonesia Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Myelofibrosis (MF) Market

• 14.1. South Korea Myelofibrosis (MF) Market Overview
• 14.2. South Korea Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Myelofibrosis (MF) Market

• 15.1. Western Europe Myelofibrosis (MF) Market Overview
• 15.2. Western Europe Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Myelofibrosis (MF) Market

• 16.1. UK Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Myelofibrosis (MF) Market

• 17.1. Germany Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Myelofibrosis (MF) Market

• 18.1. France Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Myelofibrosis (MF) Market

• 19.1. Italy Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Myelofibrosis (MF) Market

• 20.1. Spain Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Myelofibrosis (MF) Market

• 21.1. Eastern Europe Myelofibrosis (MF) Market Overview
• 21.2. Eastern Europe Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Myelofibrosis (MF) Market

• 22.1. Russia Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Myelofibrosis (MF) Market

• 23.1. North America Myelofibrosis (MF) Market Overview
• 23.2. North America Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Myelofibrosis (MF) Market

• 24.1. USA Myelofibrosis (MF) Market Overview
• 24.2. USA Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Myelofibrosis (MF) Market

• 25.1. Canada Myelofibrosis (MF) Market Overview
• 25.2. Canada Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Myelofibrosis (MF) Market

• 26.1. South America Myelofibrosis (MF) Market Overview
• 26.2. South America Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Myelofibrosis (MF) Market

• 27.1. Brazil Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Myelofibrosis (MF) Market

• 28.1. Middle East Myelofibrosis (MF) Market Overview
• 28.2. Middle East Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Myelofibrosis (MF) Market

• 29.1. Africa Myelofibrosis (MF) Market Overview
• 29.2. Africa Myelofibrosis (MF) Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Myelofibrosis (MF) Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Myelofibrosis (MF) Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Myelofibrosis (MF) Market Competitive Landscape And Company Profiles

• 30.1. Myelofibrosis (MF) Market Competitive Landscape
• 30.2. Myelofibrosis (MF) Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Myelofibrosis (MF) Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Gilead Sciences Inc.
• 31.6. A. Menarini Industrie Farmaceutiche Riunite S.r.l.
• 31.7. Incyte Corporation
• 31.8. Sobi Inc.
• 31.9. MorphoSys AG
• 31.10. CTI BioPharma Corp.
• 31.11. Suzhou Zelgen Biopharmaceutical Co. Ltd.
• 31.12. NS Pharma Inc.
• 31.13. Impact Biomedicines Inc.
• 31.14. Kartos Therapeutics Inc.
• 31.15. Geron Corporation

32. Global Myelofibrosis (MF) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Myelofibrosis (MF) Market

34. Recent Developments In The Myelofibrosis (MF) Market

35. Myelofibrosis (MF) Market High Potential Countries, Segments and Strategies

• 35.1 Myelofibrosis (MF) Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Myelofibrosis (MF) Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Myelofibrosis (MF) Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer